ECMO/CRRT combined support in the treatment of critically ill patients with novel coronavirus pneumonia

摘要

We present the cases of two patients critically ill diagnosed with novel coronavirus pneumonia (NCP). Both patients were male and met the COVID-19 diagnostic criteria in the Guidelines For the Diagnosis and Treatment of COVID-19 issued by China’s National Health Commission. The diagnosis of COVID-19 was confirmed by a positive real-time fluorescent reverse transcription–polymerase chain raction (RT–PCR) test for 2019-nCoV nucleic acid. Patients were enrolled in the study if they were in a clinically critical condition on admission and had any of the following conditions: respiratory failure requiring mechanical ventilation, shock, or failure of other organs requiring intensive care unit (ICU) care and treatment. The indication for extracorporeal membrane oxygenation (ECMO) in critically ill patients with NCP at our treatment centre was severe acute respiratory distress syndrome (ARDS) with ineffective protective pulmonary ventilation. In our procedure, ECMO and continuous renal replacement therapy (CRRT) are combined; the right femoral vein and left femoral artery are selected for V-A ECMO, and the right internal jugular vein and femoral vein are selected for V-V ECMO. ECMO assistance A MAQUET extracorporeal heart–lung machine and a heparin-coated ECMO circuit were used for bothl patients. The cannula was placed in the femoral vein and artery under direct vision. Sheaths of appropriate specifications (14F–24F for the artery and 16F–26F for the vein) were selected according to intraoperative investigation. Heparin was used to maintain an activated coagulation time (ACT) of between 180 and 220 s, and ventilator parameters and oxygen concentrations were appropriately adjusted according to the results of artery and vein blood gas analysis. Intubation and the establishment, operation, daily management, and withdrawal of ECMO/CRRT were performed by the ECMO/CRRT multidisciplinary team (MDT).